0001628280-21-003760.txt : 20210302
0001628280-21-003760.hdr.sgml : 20210302
20210302190524
ACCESSION NUMBER: 0001628280-21-003760
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210302
FILED AS OF DATE: 20210302
DATE AS OF CHANGE: 20210302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ragan Paula
CENTRAL INDEX KEY: 0001769914
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38295
FILM NUMBER: 21706088
MAIL ADDRESS:
STREET 1: C/O X4 PHARMACEUTICALS, INC.
STREET 2: 955 MASSACHUSETTS AVE., 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc
CENTRAL INDEX KEY: 0001501697
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273181608
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
BUSINESS PHONE: 857-529-8300
MAIL ADDRESS:
STREET 1: 61 NORTH BEACON STREET
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02134
FORMER COMPANY:
FORMER CONFORMED NAME: Arsanis, Inc.
DATE OF NAME CHANGE: 20100920
4
1
wf-form4_161472988864140.xml
FORM 4
X0306
4
2021-03-02
0
0001501697
X4 Pharmaceuticals, Inc
XFOR
0001769914
Ragan Paula
C/O X4 PHARMACEUTICALS, INC.
61 NORTH BEACON STREET, 4TH FLOOR
BOSTON
MA
02134
1
1
0
0
President and CEO
Common Stock
2021-03-02
4
S
0
2400
9.74
D
272923
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $9.65 to $9.92, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Of the shares of common stock reported, 101,714 shares represent unvested restricted stock units.
/s/ Derek M. Meisner, attorney-in-fact
2021-03-02